



FOR IMMEDIATE RELEASE

Early Studies Show Multiple Cycles of EBTATE are Well Tolerated and Effective in Treating Neuroendocrine Tumors

West Chester, PA, July 11, 2020-- Molecular Targeting Technologies, Inc. (MTTI) announced today that Dr. Qingxing Liu of the Department of Nuclear Medicine, Peking Union Medical College Hospital (PUMC), Beijing, China will present a talk entitled **“Peptide Receptor Radionuclide Therapy of Late-stage Neuroendocrine Tumor Patients with Multiple Cycles of ¹⁷⁷Lu-DOTA-EBTATE”** (EBTATE) at the 2020 SNMMI Virtual Annual Meeting.

The talk describes results of the safety and efficacy of multiple cycles of EBTATE with escalating doses in the treatment of patients with neuroendocrine tumors (NETs). Dr. Zhu’s team studied 32 patients in three groups with metastatic neuroendocrine neoplasms (NENs)

Qingxing Liu and Zhaohui Zhu highlighted, “Escalating doses of 1.89 GBq (50 mCi) or 3.97 GBq (100 mCi) of ¹⁷⁷Lu-DOTA-EBTATE are safe, well tolerated and significantly more effective than 1.17 GBq (30 mCi) of ¹⁷⁷Lu-DOTA-EBTATE. This complements our earlier work where the addition of Evans Blue, prolonging residence in the body, demonstrated superiority over ¹⁷⁷Lu-DOTA-TATE”

“We’re excited about this revolutionary breakthrough and thank our colleagues for their energy and passion to develop this robust therapy, promising significantly better outcomes.” said Chris Pak, President & CEO of MTTI.

MTTI received an exclusive worldwide commercialization license from NIH for this technology. This patent estate covers our ¹⁷⁷Lu-DOTA-EBTATE radiotherapeutic. Neuroendocrine neoplasm (NEN) treatment is among its potential uses.

MTTI is a privately held biotechnology company focused on the acquisition and development of novel technologies for treatment and diagnosis of human diseases. More information: www.mtarget.com. Contact: Chris Pak, Email: cpak@mtarget.com ; Tel: (610) 738-7938., J Li, Email: jli@mtarget.com

Response to ¹⁷⁷Lu-DOTA-EBTATE measured by ⁶⁸Ga-DOTA-TATE PET/CT response

EFFICACY	GROUP A (1.17 GBq)	GROUP B (1.89 GBq)	GROUP C (3.97GBq)
CR (% Complete Response)	0	0	0
PR (% Partial Response)	50	50	42.9
SD (% Stable Disease)	16.7	33.3	28.6
PD (% Progressive Disease)	33.3	16.7	28.6